Cost-Effectiveness Analysis of Rituximab

After the calculation of the costs and utilities in the previous stages, the incremental cost-utility was calculated using the following formula. To make the final decision on the cost-effectiveness of each intended drug, the ICER level was compared with the threshold.
$$\mathit{I}\mathit{C}\mathit{E}\mathit{R}\mathbf{=}\frac{\mathit{C}\mathit{o}\mathit{s}\mathit{t}\mathit{s}\mathit{o}\mathit{f}\mathit{r}\mathit{i}\mathit{t}\mathit{u}\mathit{x}\mathit{i}\mathit{m}\mathit{a}\mathit{b}-\mathit{C}\mathit{o}\mathit{s}\mathit{t}\mathit{s}\mathit{o}\mathit{f}\mathit{n}\mathit{a}\mathit{t}\mathit{a}\mathit{l}\mathit{i}\mathit{z}\mathit{u}\mathit{m}\mathit{a}\mathit{b}}{\mathit{O}\mathit{u}\mathit{t}\mathit{c}\mathit{o}\mathit{m}\mathit{e}\mathit{s}\mathit{o}\mathit{f}\mathit{r}\mathit{i}\mathit{t}\mathit{u}\mathit{x}\mathit{i}\mathit{m}\mathit{a}\mathit{b}-\mathit{O}\mathit{u}\mathit{t}\mathit{c}\mathit{o}\mathit{m}\mathit{e}\mathit{s}\mathit{o}\mathit{f}\mathit{n}\mathit{a}\mathit{t}\mathit{a}\mathit{l}\mathit{i}\mathit{z}\mathit{u}\mathit{m}\mathit{a}\mathit{b}}$$
Due to the lack of an explicit threshold for Willingness To Pay (WTP) in Iran, the WHO’s proposal for developing countries was used, i.e. the willingness to pay per QALY was one to three times the per capita Gross Domestic Product (GDP) [54 (link)]. In Iran, GDP was $ 12,547 in 2019 [55 (link)] based on which the threshold for willingness to pay was $ 37,641 (3* GDP). The Excel 2016 and TreeAge Pro 2020 software were also used for data analysis. Accordingly, TreeAge software was used to analyze the Markov model and Excel software was used to collect and summarize cost data, efficacy, and individual patient data analysis.